Why Omega-3 Trials Disagree: Dose, Product, Baseline Levels and Outcome Choice
Omega-3 trials seem to contradict each other. See how product, amount, comparator oil, participants, outcome and pooling choices explain much of the disagreement, and what they cannot explain.
Content last updated . This page has not been medically reviewed.
Four large trials side by side
| Trial | What was tested (as reported) | Comparison | People and length | Main result |
|---|---|---|---|---|
| VITAL (US) | Marine omega-3, 1 g a day, alongside vitamin D3 in a two-by-two design | Placebo | 25,871 adults (men 50 and older, women 55 and older), median 5.3 years | Major cardiovascular events: hazard ratio 0.92 (95% CI 0.80 to 1.06), not clearly different [1] |
| ASCEND (UK) | 1-g capsules of omega-3 fatty acids daily | Olive oil placebo | 15,480 adults with diabetes and no known cardiovascular disease, mean 7.4 years | Serious vascular events: rate ratio 0.97 (0.87 to 1.08) [4] |
| REDUCE-IT | Icosapent ethyl (a purified EPA ethyl ester), 2 g twice a day | Placebo | 8,179 statin-treated adults with raised triglycerides and heart disease or diabetes plus risk factors, median 4.9 years | Primary composite: hazard ratio 0.75 (0.68 to 0.83) [2] |
| STRENGTH | Omega-3 carboxylic acid (EPA plus DHA), 4 g a day | Corn oil | 13,078 statin-treated adults with high cardiovascular risk and raised triglycerides, stopped early | Primary composite: hazard ratio 0.99 (0.90 to 1.09) [3] |
REDUCE-IT and STRENGTH looked alike on paper but one used EPA alone and the other EPA plus DHA, and their comparison oils were different. [5] The reasons for their opposite results are still described as unresolved in the review we read. [5]
Why results differ
Product and form. An EPA-only ethyl ester medicine, an EPA plus DHA carboxylic acid medicine and 1-g capsules of marine omega-3 are different interventions. NCCIH notes that the composition of prescription omega-3 products is not the same as typical supplements, so their effects may not be the same. [6]
Amount. The trials above used 1 g a day in two and 4 g a day in two. Pooled reviews disagree on whether amount matters: the Cochrane review found effects did not differ by dose, while a 2021 meta-regression of 40 studies reported that the effect was dose dependent for cardiovascular events and heart attack. [7][8]
The comparison oil. Olive oil, corn oil and mineral oil have all been used as "placebo." A review of 80 studies found mineral oil's effects on blood markers inconsistent and generally not significant, and concluded it does not appear to meaningfully affect study conclusions at trial quantities, but several of its authors list the company behind the REDUCE-IT medicine as their employer. [9] Whether the comparator shaped any result is therefore argued, not settled.
Who was enrolled. VITAL enrolled adults at usual risk, ASCEND people with diabetes, and REDUCE-IT and STRENGTH statin-treated people with raised triglycerides. [1][4][2][3] Trials in one group do not transfer to the others. Proper evidence not found in the sources we read that people's starting omega-3 blood levels explain the differences between these trials; two cross-sectional samples (28 people, and 3,458 mostly US adults who tested themselves) had average blood levels of about 4.9% and 6.0%, so starting level is a reasonable question but not an answered one. [10]
The outcome counted. VITAL's primary outcome (major cardiovascular events) was not clearly different, yet a secondary analysis of total heart attack gave a hazard ratio of 0.72 (0.59 to 0.90). [1] Secondary results raise questions; they do not prove effects.
How studies are pooled. The 2020 Cochrane review of 86 trials (162,796 people, at least 12 months, including food and advice trials) found little or no effect on all-cause mortality and cardiovascular events, with possibly small reductions in coronary heart disease events (low-certainty). [7] A 2019 analysis of 13 marine omega-3 trials found lower risks of heart attack and coronary death, and said adding REDUCE-IT introduced significant heterogeneity. [11] The 2021 meta-regression found a lower heart attack risk but not a clearly lower composite (relative risk 0.95, 0.90 to 1.00). [8] Different inclusion rules and trials give different pooled answers.
Observational studies are a different question. A pooled analysis of 17 cohort studies found people with higher blood long-chain omega-3 levels had lower all-cause mortality, but these were blood levels in people living their lives, not supplement trials. [12]
What this does not mean
It does not mean omega-3 "does nothing" or "works for everything." It means each result applies to its own product, amount, group and outcome. A trial that fails for one product does not prove another product fails, and a positive trial in a high-risk group does not prove benefit for healthy people. Read the full trial summaries and omega-3 evidence by use.Frequently asked questions
Why do some studies say fish oil helps the heart and others say it does not?
They tested different products, amounts, people and outcomes, and pooled reviews used different rules. [7][11][8]
Is placebo oil a problem?
It is debated. A review found mineral oil had little consistent effect on blood markers, but several authors list the company behind the REDUCE-IT medicine as their employer. [9]
Do bigger amounts work better?
Reviews disagree. Cochrane found no difference by dose, while a 2021 meta-regression found dose-dependent effects for some outcomes. [7][8]
Does a negative trial mean omega-3 is useless?
No. It applies to that product, group and outcome. [1][4]
Should I decide from one trial?
No. Ask a clinician or pharmacist; see questions to ask.
More details: evidence, limits and cautions
The details behind this page: cautions, limits of the evidence and where sources disagree. Open any note to read it.
How to read the evidence labels
Labels used on this page: mixed, promising but limited, insufficient evidence and Proper evidence not found (we looked and found nothing usable). Amounts are study amounts as reported, never advice, and a blood marker change is not the same as fewer heart attacks.
Safety notes that vary by trial
References
- VITAL Research Group. Marine n-3 fatty acids and prevention of cardiovascular disease and cancer (VITAL). N Engl J Med 2019. Read 2026-10-23.
- REDUCE-IT investigators. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia (REDUCE-IT). N Engl J Med 2019. Read 2026-10-23.
- STRENGTH investigators. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events (STRENGTH). JAMA 2020. Read 2026-10-23.
- ASCEND Study Collaborative Group. Effects of n-3 fatty acid supplements in diabetes mellitus. N Engl J Med 2018. Read 2026-10-23.
- Zhang W et al. Unraveling the discrepancies between REDUCE-IT and STRENGTH trials with omega-3 fatty acids. Front Nutr 2024. Read 2026-10-23.
- NCCIH. Omega-3 Supplements: What You Need To Know. Read 2026-10-23.
- Abdelhamid AS et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev 2020. Read 2026-10-23.
- Bernasconi AA et al. Effect of omega-3 dosage on cardiovascular outcomes: an updated meta-analysis and meta-regression. Mayo Clin Proc 2021. Read 2026-10-23.
- Olshansky B et al. Mineral oil: safety and use as placebo in REDUCE-IT and other clinical studies. Eur Heart J Suppl 2020. Read 2026-10-23.
- Jackson KH et al. Association of reported fish intake and supplementation status with the omega-3 index. Prostaglandins Leukot Essent Fatty Acids 2019. Read 2026-10-23.
- Hu Y, Hu FB, Manson JE. Marine omega-3 supplementation and cardiovascular disease: an updated meta-analysis of 13 randomized controlled trials. J Am Heart Assoc 2019. Read 2026-10-23.
- Harris WS et al. Blood n-3 fatty acid levels and total and cause-specific mortality from 17 prospective studies. Nat Commun 2021. Read 2026-10-23.